You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Primary Hepatocellular Carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Primary Hepatocellular Carcinoma Trial (Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), camrelizumab for

Not yet recruiting
  • Primary Hepatocellular Carcinoma
  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
  • camrelizumab for Injection
  • (no location specified)
Nov 13, 2023

Hepatocellular Carcinoma Trial in Hangzhou (Fruquintinib, Sintilimab, Transcatheter arterial chemoembolization(TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Hangzhou, Zhejiang, China
    Guoliang Shao
Aug 1, 2023

Primary Hepatocellular Carcinoma, Portal Vein Thrombosis Trial (Recombinant human adenovirus type 5 + TACE)

Not yet recruiting
  • Primary Hepatocellular Carcinoma
  • Portal Vein Thrombosis
  • Recombinant human adenovirus type 5 + TACE
  • (no location specified)
May 14, 2023

Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer Trial run by the NCI (nivolumab, tadalafil, oral

Completed
  • Hepatocellular Carcinoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Advanced Hepatocellular Carcinoma Trial in Guangzhou (drug, procedure, radiation)

Not yet recruiting
  • Advanced Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Feb 7, 2023

Hepatocellular Carcinoma Trial (Donafenib + Tislelizumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Donafenib + Tislelizumab
  • (no location specified)
Sep 15, 2022

Hepatocellular Carcinoma Trial in Taipei City, Taipei (Para-Toluenesulfonamide)

Recruiting
  • Hepatocellular Carcinoma
  • Taipei City, Taiwan
  • +2 more
Mar 28, 2022

Primary Hepatocellular Carcinoma Trial in Hubei (Mixed-activated Killer Immune Cells)

Recruiting
  • Primary Hepatocellular Carcinoma
  • Mixed-activated Killer Immune Cells
  • Hubei, Wuhan, China
    Zhongnan Hospital of Wuhan University
Feb 7, 2022

Resectable Hepatocellular Carcinoma Trial in Tianjin (Camrelizumab:200mg, iv,d1 q2w;apatinib:250mg,po,qd,q2w)

Recruiting
  • Resectable Hepatocellular Carcinoma
  • Camrelizumab:200mg， iv，d1 q2w;apatinib:250mg,po，qd，q2w
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute and Hospital
Nov 3, 2021

Single-cell RNA Sequencing Resolves Regulatory Role of HBV on

Recruiting
  • HBV
  • Primary Liver Cancer
  • HBV DNA Sequencing
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
Dec 22, 2022

Liver Cancer, Liver Cirrhosis, Hepatocellular Carcinoma Trial in Saudi Arabia, Vietnam (GALAD Score)

Active, not recruiting
  • Liver Cancer
  • +3 more
  • GALAD Score
  • Jeddah, Saudi Arabia
  • +9 more
May 11, 2022

Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Metastatic Extrahepatic Bile Duct Cancer Trial in

Active, not recruiting
  • Adult Primary Hepatocellular Carcinoma
  • +6 more
  • PET scan
  • +2 more
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Jul 21, 2022

Avatrombopag for Thrombocytopenia in Patients Undergoing

Recruiting
  • Thrombocytopenia
  • Shanghai, China
    Zhongshan hospital, Fudan University
Oct 9, 2021

Hepatocellular Carcinoma Trial in Shanghai (IPM001)

Not yet recruiting
  • Hepatocellular Carcinoma
  • IPM001
  • Shanghai, Shanghai, China
    Huashan hospital Fudan university
Oct 23, 2021

Hepatocellular Carcinoma, Metastatic Cancer Trial in Makati City, Pasig City, Quezon City (GEN2 (HSV-Thymidine Kinase-m2 and

Recruiting
  • Hepatocellular Carcinoma
  • Metastatic Cancer
  • GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
  • Makati City, Philippines
  • +3 more
Mar 14, 2022

Advanced Hepatocellular Carcinoma (HCC), Gastric Cancer Metastatic to Liver, Colorectal Cancer Metastatic to Liver Trial in

Recruiting
  • Advanced Hepatocellular Carcinoma (HCC)
  • +2 more
  • Duarte, California
  • +2 more
Aug 29, 2022

Hepatocellular Carcinoma Trial (Propofol, Sevoflurane)

Recruiting
  • Hepatocellular Carcinoma
  • Kaohsiung, Taiwan
    Kaohsiung Medical University Chung-Ho Memorial Hospital
Nov 28, 2022

Hepatocellular Carcinoma (HCC) Trial in Beijing (Expanded Activated Lymphocytes (EAL), transarterial chemoembolization (TACE))

Recruiting
  • Hepatocellular Carcinoma (HCC)
  • Expanded Activated Lymphocytes (EAL)
  • transarterial chemoembolization (TACE)
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Feb 4, 2022

Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma Trial in Houston (SD-101, Pembrolizumab, Nivolumab)

Recruiting
  • Hepatocellular Carcinoma
  • Intrahepatic Cholangiocarcinoma
  • New York, New York
  • +3 more
Oct 19, 2022

Primary Liver Cancer, Non-Resectable Hepatocellular Carcinoma Trial (MRI-guided radioembolization)

Not yet recruiting
  • Primary Liver Cancer
  • Non-Resectable Hepatocellular Carcinoma
  • MRI-guided radioembolization
  • (no location specified)
Nov 1, 2022

Resectable Hepatocellular Carcinoma Trial in Tianjin (Tislelizumab combined with Lenvatinib)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • Tislelizumab combined with Lenvatinib
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute and Hospital
Apr 6, 2021

Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Solid Tumor Trial in Los Angeles (Biospecimen

Recruiting
  • Advanced Cholangiocarcinoma
  • +6 more
  • Biospecimen Collection
  • +3 more
  • Los Angeles, California
  • +1 more
Mar 31, 2023

Hepatocellular Carcinoma Trial in Yichang (Sintilimab)

Recruiting
  • Hepatocellular Carcinoma
  • Yichang, Hubei, China
    Department of Medical Oncology, Central Hospital of Yichang City
Sep 1, 2023

Hepatocellular Carcinoma, Portal Vein Thrombosis Trial in Seoul (PBT and atezolizumab/bevacizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Portal Vein Thrombosis
  • PBT and atezolizumab/bevacizumab
  • Seoul, Korea, Republic of
    Samsung Medical Center
Nov 15, 2022

Primary Liver Cancer, Radiofrequency Ablation, Immunotherapy Trial in Guangzhou (Neo-MASCT)

Recruiting
  • Primary Liver Cancer
  • +3 more
  • Neo-MASCT
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Jan 10, 2022